Abstract
Ischemic brain damage develops at a pace slower than previously believed. In the penumbral area of the ischemic territory after focal ischemia, or in selectively vulnerable regions following transient global ischemia, cell death occurs hours or days following the acute insult. The process is the result of a complex cascade of pathogenic events, in which local and systemic factors play a role. Early and late excitotoxicity, apoptosis and inflammation have been found to contribute to the maturation of the damage. Mechanisms include calcium overload, oxidative stress, mitochondrial dysfunction, as well as damage to DNA, structural proteins and enzymes. Ischemic brain injury can be counteracted, totally or in part, by appropriate therapeutic interventions, resulting in varying degrees of neuroprotection in animal models. Although clinical trials based on neuroprotective agents have been disappointing, therapeutic strategies targeting recently identified pathogenic processes offer new hope. These approaches, alone or in combination with therapies based on early reperfusion of the ischemic brain, are likely to provide powerful tools for the treatment of human stroke.
Keywords: brain ischemia, penumbra, maturation phenomenon, excitotoxicity, oxidative stress, inflammation, programmed cell death, neuroprotection
Current Neuropharmacology
Title: Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions
Volume: 2 Issue: 3
Author(s): Francesco Orzi, Giuliano Sette, Ping Zhou and Costantino Iadecola
Affiliation:
Keywords: brain ischemia, penumbra, maturation phenomenon, excitotoxicity, oxidative stress, inflammation, programmed cell death, neuroprotection
Abstract: Ischemic brain damage develops at a pace slower than previously believed. In the penumbral area of the ischemic territory after focal ischemia, or in selectively vulnerable regions following transient global ischemia, cell death occurs hours or days following the acute insult. The process is the result of a complex cascade of pathogenic events, in which local and systemic factors play a role. Early and late excitotoxicity, apoptosis and inflammation have been found to contribute to the maturation of the damage. Mechanisms include calcium overload, oxidative stress, mitochondrial dysfunction, as well as damage to DNA, structural proteins and enzymes. Ischemic brain injury can be counteracted, totally or in part, by appropriate therapeutic interventions, resulting in varying degrees of neuroprotection in animal models. Although clinical trials based on neuroprotective agents have been disappointing, therapeutic strategies targeting recently identified pathogenic processes offer new hope. These approaches, alone or in combination with therapies based on early reperfusion of the ischemic brain, are likely to provide powerful tools for the treatment of human stroke.
Export Options
About this article
Cite this article as:
Orzi Francesco, Sette Giuliano, Zhou Ping and Iadecola Costantino, Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359648
DOI https://dx.doi.org/10.2174/1570159043359648 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface [Hot topic: Potential Therapeutic Agents for Parkinsons Disease (Executive Editor: Masato Asanuma)]
Current Pharmaceutical Design Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology Imbalance and Management of Iron Homeostasis and the Intervention of Chinese Medicine in Intracerebral Hemorrhage: A Review
Current Traditional Medicine Post Dural Puncture Headache and Hypertension
Current Hypertension Reviews Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Reversal of Oxidative Stress in Neural Cells by an Injectable Curcumin/Thermosensitive Hydrogel
Current Drug Delivery Regulation of Neurogenesis and Angiogenesis in Depression
Current Neurovascular Research Ginkgo Biloba Extract (EGb 761) and CNS Functions Basic Studies and Clinical Applications
Current Drug Targets Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Ion Channels on Microglia: Therapeutic Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets The Activated Endocannabinoid System in Atherosclerosis: Driving Force or Protective Mechanism?
Current Drug Targets PPARγ-targeting Potential for Radioprotection
Current Drug Targets Editorial (Hot Topic: Bioactive Components of Plant Products Including Polyphenols Exert Neuroprotective Effects and Benefit Neural Function)
Central Nervous System Agents in Medicinal Chemistry Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Postoperative Delirium
Current Drug Targets Safety of Using Copper Oxide in Medical Devices and Consumer Products
Current Chemical Biology Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer
Current Topics in Medicinal Chemistry